WallStreetZenWallStreetZen

NASDAQ: GLPG
Galapagos Nv Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for GLPG

Based on 2 analysts offering 12 month price targets for Galapagos Nv

Min Forecast
$32.00-5.55%
Avg Forecast
$36.00+6.26%
Max Forecast
$40.00+18.06%

Should I buy or sell GLPG stock?

Based on 2 analysts offering ratings for Galapagos Nv.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 50%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although GLPG's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates GLPG as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their GLPG stock forecasts and price targets.

GLPG stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-07
lockedlocked$00.00+00.00%2025-10-21

1 of 1

Forecast return on equity

Is GLPG forecast to generate an efficient return?

Company
N/A
Industry
352.12%
Market
211.34%

Forecast return on assets

Is GLPG forecast to generate an efficient return on assets?

Company
N/A
Industry
122.26%

GLPG earnings per share forecast

What is GLPG's earnings per share in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
-$1.80
Avg 2 year Forecast
-$2.77
Avg 3 year Forecast
-$0.13

GLPG revenue forecast

What is GLPG's revenue in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
$281.9M-16.8%
Avg 2 year Forecast
$266.3M-21.41%
Avg 3 year Forecast
$282.3M-16.69%
GLPG's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GLPG revenue growth forecast

How is GLPG forecast to perform vs Biotechnology companies and vs the US market?

Company
-6.46%
Industry
116.92%
Market
23.08%
GLPG's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GLPG's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GLPG vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GLPG$33.88$36.00+6.26%Buy
MESO$17.25N/AN/A
IMNM$24.62$31.22+26.82%Strong Buy
RCUS$21.04$30.75+46.15%Buy
RXRX$4.19$9.50+126.73%Strong Buy
View Top Biotech Stocks

Galapagos Nv Stock Forecast FAQ

Is Galapagos Nv Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: GLPG) stock is to Buy GLPG stock.

Out of 2 analysts, 0 (0%) are recommending GLPG as a Strong Buy, 1 (50%) are recommending GLPG as a Buy, 1 (50%) are recommending GLPG as a Hold, 0 (0%) are recommending GLPG as a Sell, and 0 (0%) are recommending GLPG as a Strong Sell.

If you're new to stock investing, here's how to buy Galapagos Nv stock.

What is GLPG's earnings growth forecast for 2026-2028?

(NASDAQ: GLPG) Galapagos Nv's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.

Galapagos Nv's earnings in 2026 is -$506,924,418.On average, 12 Wall Street analysts forecast GLPG's earnings for 2026 to be -$118,331,370, with the lowest GLPG earnings forecast at -$383,600,030, and the highest GLPG earnings forecast at $114,166,676. On average, 9 Wall Street analysts forecast GLPG's earnings for 2027 to be -$182,462,400, with the lowest GLPG earnings forecast at -$302,685,016, and the highest GLPG earnings forecast at -$66,839,399.

In 2028, GLPG is forecast to generate -$8,810,438 in earnings, with the lowest earnings forecast at -$8,467,774 and the highest earnings forecast at -$9,074,027.

What is GLPG's revenue growth forecast for 2026-2028?

(NASDAQ: GLPG) Galapagos Nv's forecast annual revenue growth rate of -6.46% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.08%.

Galapagos Nv's revenue in 2026 is $334,866,279.On average, 13 Wall Street analysts forecast GLPG's revenue for 2026 to be $18,575,725,344, with the lowest GLPG revenue forecast at $17,113,469,339, and the highest GLPG revenue forecast at $20,302,228,604. On average, 10 Wall Street analysts forecast GLPG's revenue for 2027 to be $17,547,072,066, with the lowest GLPG revenue forecast at $13,328,341,580, and the highest GLPG revenue forecast at $19,166,163,100.

In 2028, GLPG is forecast to generate $18,599,448,290 in revenue, with the lowest revenue forecast at $14,022,237,738 and the highest revenue forecast at $22,107,808,350.

What is GLPG's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: GLPG) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 122.26%.

What is GLPG's Price Target?

According to 2 Wall Street analysts that have issued a 1 year GLPG price target, the average GLPG price target is $36.00, with the highest GLPG stock price forecast at $40.00 and the lowest GLPG stock price forecast at $32.00.

On average, Wall Street analysts predict that Galapagos Nv's share price could reach $36.00 by Nov 7, 2026. The average Galapagos Nv stock price prediction forecasts a potential upside of 6.26% from the current GLPG share price of $33.88.

What is GLPG's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: GLPG) Galapagos Nv's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that GLPG's EPS will be -$1.80 for 2026, with the lowest EPS forecast at -$5.82, and the highest EPS forecast at $1.73. On average, analysts forecast that GLPG's EPS will be -$2.77 for 2027, with the lowest EPS forecast at -$4.59, and the highest EPS forecast at -$1.01. In 2028, GLPG's EPS is forecast to hit -$0.13 (min: -$0.13, max: -$0.14).

What is GLPG's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: GLPG) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.